SciSparc Ltd 6-K, filed Dec 2, 2020
SciSparc Ltd. (SPRC)
About this 6-K
SciSparc Ltd filed this 6-K on December 2, 2020.
UNITEDSTATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of December 2020
Commission file number: 001- 38041
THERAPIX BIOSCIENCES LTD.
(Translation of registrant’s name into English)
16 Abba Hillel Road
Ramat Gan 5250608, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
On December 2, 2020, Therapix Biosciences Ltd. (“Therapix” or the “Company”) issued a press release titled: “Therapix Biosciences to Collaborate with The University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain.” A copy of this press release is furnished herewith as exhibit 99.1.
On November 30, 2020, Therapix issued a letter from Therapix’s Chief Executive Officer to its shareholders. A copy of this letter is furnished herewith as exhibit 99.2.
1
EXHIBITINDEX
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Therapix Biosciences Ltd. | ||
|---|---|---|
| Date: December 2, 2020 | By: | /s/ Oz Adler |
| Name: Oz Adler | ||
| Title: Chief Financial Officer |
3
Exhibit 99.1
Therapix Biosciences to Collaborate withThe University of Calgary to Further Examine its Proprietary Drug Candidate THX-160 for Pain
“In the era of America’sdeadly opioid crisis, cutting-edge pain therapeutics like THX-160 possess the potential to be a new and effective treatment optionfor pain patients, reducing the risks of opiate addiction.”
TELAVIV, Israel, December 2, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (“Therapix” or the “Company”) (OTC Pink: TRPXY), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced a collaboration between the company and The University of Calgary to further evaluate the analgesic effect of Therapix’s CB2R agonist proprietary drug candidate, THX-160.
This collaboration is expected to facilitate the further development of THX-160 for the treatment of pain, following efficacy pre-clinical studies that demonstrated the analgesic advantages of THX-160 over control. Moreover, THX-160’s anti-analgesic effects, in these studies, were comparable and even greater in some instances over high-dose morphine analgesic effects.
Therapix’s drug candidate THX-160 is an innovative CB2 receptor agonist, which was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, head of the Medicinal Chemistry Lab and the President of Multidisciplinary Center for Cannabinoid Research and a recipient of the Israel Prize in Exact Sciences - Chemistry and EMET Prize in Exact Sciences – Chemistry, as well as a member of the Therapix Scientific Advisory Board.
“Although cannabinoids have therapeutic potential, their psychoactive effects, associated with the usage of CB1 receptor (CB1R) agonists, have largely limited their use in clinical practice; CB2 receptors (CB2R) agonists do not cause such effects. Quite the opposite, CB2R agonists are known to exhibit mainly a protective effect, acting on pain, in inflammation, in neurological diseases and in many other disease states,” stated Prof. Mechoulam. “For that reason, I have synthesized in my laboratory a molecule (HU-433; THX-160), which does not activate the CB1 receptor, but affects CB2R alone. This molecule was shown in pre-clinical studies performed by Therapix to lower pain significantly. I believe that our new molecule, which so far has not shown any undesirable effects in animal studies, holds a significant promise to become a major drug as it uses a natural pathway to oppose pain.”
“We are excited to partner on this project with the University of Calgary under the leadership of Dr. Tuan Trang, Associate Professor in the Department of Comparative Biology & Experimental Medicine at the University of Calgary and a renowned researcher in the clinical management of pain conditions. We believe this research could further demonstrate the analgesic clinical utility of THX-160,” said Dr. Adi Zuloff-Shani, Chief Technologies Officer of Therapix. “In the era of America’s deadly opioid crisis and following the declaration of a nationwide public health emergency and in fitting with the five-point opioid strategy formed to address the national opioid crisis, cutting-edge pain therapeutics like THX-160 possess the potential to be a new and effective treatment option for pain patients, and reduce the risks of opiate addiction.”
About Therapix Biosciences (OTC Pink: TRPXY):
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Please visit our website for more information at www.therapixbio.com, the content of which is not a part of this press release.
Forward-Looking Statements:
This press release contains forward-lookingstatements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses the potentialbenefits and results arising from the collaboration and the potential success and the potential efficacy, effects and benefitsof THX-160 and its potential to become a major drug and become a new and effective treatment option. Because such statements dealwith future events and are based on the Company’s current expectations, they are subject to various risks and uncertaintiesand actual results, performance or achievements of the Company could differ materially from those described in or implied by thestatements in this press release. The forward-looking statements contained or implied in this press release are subject to otherrisks and uncertainties, including those discussed under the heading “Risk Factors” the Company’s Annual Reporton Form 20-F filed with the SEC on June 15, 2020, and in subsequent filings with the U.S. Securities and Exchange Commission. Exceptas otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements,which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com
Exhibit 99.2
Therapix Biosciences Issues CEO Letterto its Shareholders
TEL AVIV, Israel, November 24, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (OTC Pink: TRPXY) (the “Company”), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based pharmaceuticals, today released a letter to its shareholders from its Chief Executive Officer, Mr. Amitay Weiss.
Dear Shareholders,
I am pleased to reach out for the first time since I was appointed CEO and as the company enters its exciting new chapter ahead. Recently, the company’s Board of Directors and CEO were replaced by a new, motivated and experienced team; one that is committed to turning the company around and steering it in the right direction.
I can imagine that some of you experienced many disappointments in the past years. That said, after close examination of the company’s priorities, I am confident that the new management (me included) possesses the right tools to reach the company’s true potential and provide value to its shareholders.
Our first priority was to ensure the company’s future by reinforcing its financial strength and establishing a budget that will allow us to achieve notable milestones. Recently, we announced a $4.2 million equity offering.
Strengthening the company’s financial structure will allow us to work towards advancing our technology and pursuing strategic opportunities including expanding our pipeline by exploring ways to strengthen our portfolio through internal and external business growth strategies of innovative technologies and products, given sufficient capital for funding.
Currently the company has several pre-clinical and clinical programs in its high potential R&D pipeline. Additionally, the company also has a valuable asset addressing the supplement market; CannAmide^TM^; an Endocannabinoid-like compound with a broad spectrum of pharmacological properties. CannAmide^TM^ has been designated a product license issuance from the Natural and Non-prescription Health Products Directorate (NNHPD) from Health Canada. We are now investigating commercialization of the product in Canada and other jurisdictions.
We intend to maximize every asset the company holds through commercialization, advancing clinical programs, licensing agreements, new partnerships and more. Our only focus is to rehabilitate Therapix and restore your trust in the company and its management so that we can together reach its full potential.
Sincerely yours,
Amitay Weiss
Investor Contact:
IR@therapixbio.com
Tel: +972-3-6167055
info@therapixbio.com
Forward-Looking Statements:
This letter contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses its future plans and goals, including reaching the company’s potential, providing value to shareholders, advancing technology and pursuing strategic opportunities, maximizing the company’s assets and rehabilitating the company. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this letter. The forward-looking statements contained or implied in this letter are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” the Company’s Annual Report on Form 20-F filed with the SEC on June 15, 2020, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.